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Abstract
2-Hydroxypropyl-Beta-Cyclodextrin (HPβCD) can be used to treat Niemann-Pick type C dis-
ease, Alzheimer’s disease, and atherosclerosis. But, a consequence is that HPβCD can
cause hearing loss. HPβCD was recently found to be toxic to outer hair cells (OHCs) in the
organ of Corti. Previous studies on the chronic effects of in vivo HPβCD toxicity did not know
the intra-cochlear concentration of HPβCD and attributed variable effects on OHCs to indi-
rect drug delivery to the cochlea. We studied the acute effects of known HPβCD concentra-
tions administered directly into intact guinea pig cochleae. Our novel approach injected
solutions through pipette sealed into scala tympani in the cochlear apex. Solutions were
driven along the length of the cochlear spiral toward the cochlear aqueduct in the base. This
method ensured that therapeutic levels were achieved throughout the cochlea, including
those regions tuned to mid to low frequencies and code speech vowels and background
noise. A wide variety of measurements were made. Results were compared to measure-
ments from ears treated with the HPβCD analog methyl-β-cyclodextrin (MβCD), salicylate
that is well known to attenuate the gain of the cochlear amplifier, and injection of artificial
perilymph alone (controls). Histological data showed that OHCs appeared normal after
treatment with a low dose of HPβCD, and physiological data was consistent with attenuation
of cochlear amplifier gain and disruption of non-linearity associated with transferring acous-
tic sound into neural excitation, an origin of distortion products that are commonly used to
objectively assess hearing and hearing loss. A high dose of HPβCD caused sporadic OHC
losses and markedly affected all physiologic measurements. MβCD caused virulent destruc-
tion of OHCs and physiologic responses. Toxicity of HPβCD to OHC along the cochlear
length is variable even when a known intra-cochlear concentration is administered, at least
for the duration of our acute studies.
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Introduction
2-Hydroxypropyl-Beta-Cyclodextrin (HPβCD) is a commonly used excipient to stabilize and
solubilize pharmaceuticals. HPβCD reduces cholesterol and lipid accumulation, and has
emerged as a possible treatment for Niemann-Pick type C disease, Alzheimer’s disease, and
atherosclerosis [1–4]. But, a negative side effect of HPβCD-based treatments is hearing loss.
Recent studies on the chronic effects of HPβCD administered systemically or directly into
cerebrospinal fluid found graduated losses of outer hair cells (OHC) along the cochlear spiral,
with more severe losses at the cochlear base than the apex [5–6]. While the origins of HPβCD
toxicity within the ear remain uncertain, its effects can modulate cochlear or OHC electrome-
chanics in excised cochleae [7–8]. In experiments reported here we used a variety of physiolog-
ical measurements to understand the effects of acute administration of HPβCD, and HPβCD
analog methyl-β-cyclodextrin (MβCD), directly into cochlear perilymph. Results were com-
pared to measurements made during treatment with salicylate, which has effects that have
been well characterized, and the effects of injecting artificial perilymph alone.
Methods
Animal preparation
We used NIH-strain pigmented guinea pigs of either sex (between 400–600 g). Initially animals
were anesthetized with an intraperitoneal injection of sodium thiobutabarbital (100 mg/kg).
Cutting shears were used to shave head and neck fur. A tracheotomy was performed, and the
animal was artificially ventilated with isofluorane (~1% in oxygen) with respiratory volume
maintained (5% end-tidal CO2). We monitored heart rate, O2 saturation, and expired CO2 level
with a pulseoximeter/CO2 analyzer. The right cochlea was accessed with a ventral surgical
approach. Soft tissue of the right ear canal was removed. The animal was mounted with hollow
ear bars that allowed delivery of acoustic stimuli. A cannula placed in the left jugular vein was
used to administer pancuronium bromide (0.06 mg/kg) to eliminate middle-ear muscle con-
tractions just before the start of making auditory measurements. Body temperature was main-
tained (38˚C) with a dc-powered heating blanket and rectal thermometer system. Experimental
protocols for this study were approved by the Animal Studies Committee of Washington Uni-
versity (protocol numbers 20120113 and 20130069).
Solution administration by injection into the cochlear apex
Ototoxic solutions were administered from a pipette sealed into the cochlear apex. Previously
we have shown that apical injection drives solutions toward the cochlear aqueduct at the base
of scala tympani, allowing the entire scala to be uniformly treated [9–11]. This overcomes the
limitations of classic administration techniques to the cochlear base that do not reach thera-
peutic levels at the regions tuned to mid to low frequencies that code speech vowels and back-
ground noise. Administering into the cochlear base is certainly not the ideal approach to
understand how HPβCD affects the entire cochlear length [11–16]. Solutions injected into the
cochlear apex can be administered slowly if the goal of the experiment is to sequentially affect
finely spaced cochlear regions contributing to a response [10–11]. For the experiments
reported here, we used a constant, relatively fast (0.5 μL/min) injection rate.
Animals received either artificial perilymph alone (controls, n = 3 guinea pigs) or, in artifi-
cial perilymph, 20 mM salicylate (n = 3 guinea pigs), 13 mM HPβCD (n = 3 guinea pigs), 27
mM HPβCD (n = 3 guinea pigs), or 13 mM MβCD (n = 3 guinea pigs). The composition (in
mM) of artificial perilymph was NaCl (127.5), KCl (3.5), NaHCO3 (25), CaCl2 (1.3), MgCl2
(1.2), NaH2PO4 (0.75), and Glucose (11) [10]. Animals treated with 13 mM HPβCD were in
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the “low-dose” group and those treated with 27 mM HPβCD were in the “high-dose” group.
Salicylate alters surface cisternal system of hair cell bodies [17], reduces turgor pressure [18],
and effects OHC motility [19]. In short, salicylate attenuates the gain of the cochlear amplifier.
Solutions were injected from a pipette sealed into the cochlear apex in the 4th cochlear turn.
The mucosa covering the apex was removed with a damp, cotton wrapped applicator or cellu-
lose wipe. Cyanoacrylate glue was applied to the dry bone of the apex, then a thin layer two-
part silicone elastomer was applied. This effectively made the surface hydrophobic. The
cochlear apex was fenestrated through the adhesive layers on the bone. The fenestration was
made with a 30º, 1/3mm oval window pick by resting the pick on the surface at one location
and then lifting the pick off the surface. The fenestra diameter was made to fit a 20–30 μm
diameter tip pipette that was pulled from 100 mm x 0.58 mm inner-diameter glass tubing. We
made a fluid-tight seal between the glass injection pipette and the hydrophobic surface by
wicking fluid (accumulated from either condensation or cochlear fluid accumulation) and
applying additional cyanoacrylate glue. Solutions were driven at 500 nL/min for 15 min for a
total of 7500 nL through a 50 μL Hamilton gas-tight syringe (1710TLL), glued to a World Pre-
cision Instruments plexiglass coupler (MPH6S10), mounted on a computer-controlled World
Precision Instruments Ultrapump.
Acoustic stimuli and physiologic measurements
Electrophysiologic measurements were made using procedures that we have previously
described [9–11]. Measurements were made with Tucker-Davis System 3 hardware controlled
by custom-written software in Visual Basic (Microsoft) on a personal computer. TD-RP2
modules were used for stimulus generation. Stimuli were passed through TD-PA5 attenuators,
and TD-HB7 headphone amplifiers. Acoustic stimuli were delivered in a closed sound system:
an Etymotic ER-10C coupled to the hollow ear bar. Calibrations were completed in individual
ears by tracking 70 dB SPL tones from 125 Hz to 26 kHz in ¼ octave steps. Cochlear response
measurements were made differentially between an Ag/AgCl electrode in the round window
niche and a platinum-needle electrode in the vertex. Measurements were made with an
optically-coupled TD-HB7amplifier (1000X gain, 0.005–15 kHz bandpass filter), routed to
TD-RP2 modules for digitization (48.8 kHz) and averaging. Animals were electrically
grounded with an Ag/AgCl pellet electrode coupled to the exposed soft tissue of the neck by a
fluid bridge.
Histological preparation
At the conclusion of the apical injection experiments, the experimental cochleae were prepared
for fixative injection. The pipette used to inject ototoxins was removed, and the fenestration
was occasionally enlarged to a small extent to accept a 20–30 μm diameter tip pipette pulled
from 100 mm x 0.58 mm inner-diameter glass tubing used to inject fixative. The pipette for fix-
ative was sealed into the cochlea by wicking away any cochlear or condensation fluid accumu-
lation while applying cyanoacrylate glue to form a fluid-tight junction. The round window
membrane was perforated before the start of fixative injection. We injected 2.5% glutaralde-
hyde and 1.5% paraformaldehyde in a 0.065 M phosphate buffer. This solution was injected at
2000 nL / min for a total of 7500 nL. Cochleae were extracted and placed in fixative solution
for at least two days at 4˚C. Cochleae were decalcified (0.1 M EDTA with 0.4% glutaradehyde)
for 14 days, osmicated (1% OsO4 in dH2O) for 60 minutes, dehydrated in ethanols and propyl-
ene oxide, embedded in Araldite resins, and sectioned parallel to the spiral axis of the fourth
cochlear turn at 40 μM with a carbide steel knife. Sections were mounted in Permount on
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microscope slides and cover-slipped. Sections were analyzed with light microscopy by an
author who was blinded to the treatment each ear received.
Results
The time course of cochlear action potential (CAP) threshold shifts differed across treatments
and tone-burst frequencies (Fig 1). The10 dB threshold shifts occurring 30 minutes after the
start of injecting artificial perilymph alone (control experiments) quantify the extent to which
the apical injection procedure itself influenced neural thresholds. The direction and rate (dB /
min) of CAP threshold shifts differed between HPβCD 13 and 27 mM treatments, in that
threshold shifts essentially raised and then plateaued for 13 mM treatment or, in contrast,
steadily increased to a maximum or to the abolition of CAPs for 27 mM treatment. Quick
CAP threshold shifts followed by gradual CAP recovery is consistent with the well-known tem-
porary effects of salicylate (e.g., [20–21]. Maximal effects of salicylate and 27 mM HPβCD on
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Fig 1. Cochlear action potential (CAP) threshold shifts as a function of time before, during, and after
apical injection of various ototoxic solutions. Semi-transparent blue rectangles spanning 0 to 15 minutes
identify when apical injections occurred. There were a total of three ears from three guinea pigs in each of the
five groups.
https://doi.org/10.1371/journal.pone.0175236.g001
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of prestin in mice raise neural threshold by 40 to 60 dB [22–23]. Average threshold shifts of 20
to 40 dB from 13 mM HPβCD are far greater than the 6 dB threshold shifts caused by heterozy-
gote prestin knockout mice when electromotility is halved [22]. Total CAP abolition during,
or soon after, MβCD treatment is itself an indication of far greater effects than simple cochlear
amplifier gain attenuation (see the histological data from these ears presented later). In normal
ears CAP to low-level tone bursts originate from the peak of the traveling wave (reviewed in
[24]). Across all toxic treatments, CAP thresholds to 2, 4, and 8 kHz started to rise soon after
the injection start (i.e., zero minutes re. injection start), but ~3–8 additional minutes was
needed to start abolishing CAP thresholds to 16 kHz. This demonstrates that we did not simul-
taneously treat the length of the cochlea. Comparing maximal effects on CAP threshold shifts
in Fig 1 helps to understand the extent to which cochlear amplifier gain was attenuated across
treatments.
Auditory Nerve Overlapped Waveform (ANOW) measurements (Fig 2) show that the api-
cal injection technique can treat the apical half of the cochlear spiral, a region that classic
round window administration cannot [11]. The ANOW originates from afferent auditory
nerve fibers in the apical cochlear half and can quantify low-frequency auditory thresholds [10,
25]. ANOW amplitudes from supra-threshold, 50 dB SPL sound levels were ablated by salicy-
late, HPβCD, and MβCD treatments, but not by artificial perilymph alone (control; Fig 2).
Subtle changes to ANOW from control ears during the time of injection suggest that perhaps
some ANOW changes in ears treated with toxic solutions resulted from mechanical distur-
bances from the fast apical injection approach used for these experiments. Nevertheless, unlike
CAPs, ANOW amplitude measurements were fully abolished with all four treatments, consis-
tent with the ANOW being more sensitive than CAPs to cochlear manipulations and diseased
states [26].
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Fig 2. Auditory Nerve Overlapped Waveform (ANOW) amplitude measurements. The blue, semi-
transparent rectangle identifies the 15 minute duration of apical injections. The values presented on the far left
of the figure are average amplitude measurements from the ~10 minutes of data before the injection start. The
ranking of measurements on the y-axis corresponds to the effect of the solution, with the measurements
associated with the smallest effect at the top of the figure, progressing to the largest effect at the bottom of the
figure. Salicylate, HPβCD, and MβCD treatments caused total abolition of ANOW, but artificial perilymph
alone (control) did not. N = 3 for each treatment group.
https://doi.org/10.1371/journal.pone.0175236.g002
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Cochlear microphonic (CM) measurements to 90 dB SPL 500 Hz tone bursts were made
from inside the endolymphatic space where responses are not influenced by neural excitation
to the sound used to evoke the desired hair-cell-based response [10]. Slight transient changes
in CM amplitude from control, 13 mM HPβCD, and salicylate treatment are consistent with
slight mechanical disruption caused by the relatively fast injection rate that was used here. The
CM remaining after treatment with 27 mM HPβCD originates from current flow through
remaining OHC and IHC, perhaps IHCs more than OHCs (as suggested from histological
data below). Total abolition of CM measurements occurred for MβCD.
Endocochlear potential (EP) measurements were made in the third cochlear turn (Fig 3).
Artificial perilymph injection (control) did not markedly affect the EP. Treatment with 13 mM
HPβCD and salicylate caused transient and temporary effects: 13 mM HPβCD caused EP to
increase during injection and then returned to pre-injection values during the time immedi-
ately after injection while, in contrast, salicylate caused EP to decrease before gradually return-
ing toward pre-injection values. Treatment with 27 mM HPβCD moderately affected the EP,
causing transient increases during injection that returned to pre-injection values during the
time immediately after injection before markedly declining further. MβCD caused a brief
increase in EP then total abolition before the injection was complete. EP changes are mirrored
by changes in the magnitude of the silent current, e.g., an EP decrease is consistent with a
decrease in the standing current through outer hair cells in silence [27]. The time courses of
effects on EP during treatment are not identical to the time courses of effects on CM (cf. Figs 3
and 4), which is consistent with the origin of these measurements being different even though
they were made with the same electrode in the endolymphatic space of the third cochlear turn.
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Fig 3. Endocochlear potential (EP) measured from inside the endolymphatic space of the third
cochlear turn. The blue rectangle identifies the 15-minute injection. Voltages to the left of the rectangle are
the average EP from ~10 minutes before the injection start. Measurement ranks along the y-axis indicate
which solution caused the largest effect, smallest effects are at the top of the figure and largest effects at the
bottom. Injection of artificial perilymph alone (control) did not affect EP. Injection of 13 mM HPβCD and
salicylate caused slight and temporary effects. Treatment with 27 mM HPβCD did not abolish the EP but
MβCD caused total abolition. N = 3 for each treatment group.
https://doi.org/10.1371/journal.pone.0175236.g003
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Cubic DPOAE amplitudes were measured at 2f1- f2 with an arbitrarily chosen f2 6 kHz
(Fig 5). Individual-ear DPOAE amplitude fine structure was considered by choosing the f2 pri-
mary-tone frequencies closest to 6 kHz that produced a peak in the 2f1- f2 DPOAE amplitude.
Injection of artificial perilymph did not affect DPOAE amplitudes in control ears. With 13
mM HPβCD treatment, DPOAE amplitudes dramatically declined during the injection but
gradually recovered toward near pre-injection levels. With salicylate and 27 mM HPβCD treat-
ments, effects on DPOAE amplitude were longer, and did not fully recover. MβCD was the
only treatment that totally abolished DPOAE amplitudes.
Sensory cells within the organ of Corti were evaluated using light microscopy and serial sec-
tions of plastic embedded cochleae (Fig 6). All sensory and non-sensory cells were well pre-
served in the control and 13 mM HPβCD groups. Effects from treatment with 27 mM HPβCD
were variable, ranging from well-preserved to severely damaged outer and inner hair cells.
Ears with severe IHC and OHC damage had greater effects at the base than apex (Fig 7). While
some of this variability in OHC loss may be attributable to the relatively short time-frame of
our acute study, interanimal variability is nevertheless consistent with that reported from
Crumling et al. [5] and Cronin et al. [6] who studied the chronic effects of HPβCD treatment.
Treatment with MβCD consistently caused severe damage directly to the OHCs and IHCs or
the regions around these sensory cells. During the time course of these experiments with
HPβCD, MβCD, or artificial perilymph (controls), lateral wall structures, including the spiral
ligament fibrocytes, stria vascularis, spiral ganglion neurons did not appear to be altered.
TIME re. INJECTION START (min)
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Fig 4. Cochlear microphonic (CM) measured from inside the endolymphatic space of the third
cochlear turn. The semi-transparent blue rectangle identifies the 15 minute injection duration. Values listed
on the far left of the figure are average amplitude measurements from the ~10 minutes of data collected
before the start of injection. The ranking of measurements on the y-axis corresponds to the solution effect,
with the measurements associated with the smallest effect at the top of the figure, progressing to the largest
effect at the bottom of the figure. The noise floor for these CM measurements is approximately -85 dB, or ~35
dB down from the average amplitude measurements calculated from the 10 minutes of data before the
injection start, which are those values presented on the far left of the figure. Artificial perilymph alone (control)
and 13 mM HPβCD did not cause marked effects on CM amplitude, salicylate caused slight and temporary
effects, 27 mM HPβCD did not fully abolish the CM but MβCD caused total abolition. Data were obtained from
three ears for each treatment group.
https://doi.org/10.1371/journal.pone.0175236.g004
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Specific morphometry was not performed in these structures, but there was no evidence of
stria swelling or fluid leakage, the spiral ligament fibrocytes populated the ligament as in con-
trol ears, and there were no signs of myelin unwrapping from the spiral ganglion cell soma or
evidence of cell swelling. Histological analysis was not performed for treatment with salicylate
as the effects are well known or well-characterized [13, 21].
Discussion
Our apical injection procedure overcomes the limitations of classical approaches of adminis-
trating drug treatments to the more surgically accessible cochlear base. In particular, apically
injected solutions can treat the entire length of the cochlear spiral. We studied the acute effects
of injecting HPβCD, and HPβCD analog MβCD, directly into the cochlea. We injected ~2x the
volume of guinea pig scala tympani, most of which would have been driven out with our tech-
nique through cochlear aqueduct during the injection duration. The experiments ended and
the animals were sacrificed 60 minutes after the start of treatment. Results were compared to
those from salicylate treatments, as well as artificial perilymph alone (controls). Treatment
with 13 and 27 mM HPβCD and salicylate ablated the ANOW amplitude and raised CAP
thresholds by approximately 40 to 60 dB, consistent with attenuation of cochlear amplifier
gain. Other measurements such as the endocochlear potential, cochlear microphonic recorded
from inside the third cochlear turn endolymphatic space, distortion product otoacoustic emis-
sions from the ear canal, and histological measurements generally showed that effects from
MβCD were greatest, followed in order of decreasing effect by 27 mM HPβCD, 13 mM
HPβCD, salicylate, and artificial perilymph injections alone (controls).
TIME re. INJECTION START (min)
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Fig 5. Distortion product otoacoustic emission (DPOAE) amplitudes at 2f1- f2 evoked from f2 6 kHz, f2 /
f1 = 1.2 kHz, L2 = 50 dB, L1 = 10 dB re. L2. The blue rectangle identifies the 15 minute injection. Values to the
left of the rectangle are average DPOAE amplitudes from ~10 minutes of pre-injection data. The microphone
noise floor was approximately -20 dB SPL. Measurement rankings on the y-axis were determined by the effect of
the ototoxic solution: measurements associated with the smallest effect are at the top of the figure, progressing
to the largest effect at the bottom of the figure. MβCD totally abolished DPOAEs, while the remaining ototoxic
solutions caused transient declines in amplitudes that did not return to pre-injection levels. N = 3 for each
treatment.
https://doi.org/10.1371/journal.pone.0175236.g005
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HPβCD effects on an analysis of the electrical cochlear response
Here we address how treatment with 13 mM HPβCD affected harmonic distortion in the elec-
trical cochlear response measured with a round window electrode. Sigmoidal, saturating, non-
linear functions are commonly used in analyses of empirical, gross measurements to study
general transfer of acoustic sound into neural excitation (fTR, e.g., [9–10, 15, 24, 28–29]). Even
and odd order distortions respectively associate with the asymmetry and saturation of in vivo
fTR [30] and analyses of distortions can be used to estimate the operating point of fTR that is
associated with the amplitude of distortion products (e.g., [31–32]. Expressing an even order
Fig 6. Histology of second cochlear turn organ of Corti from exemplar ears after apical injection of artificial
perilymph (control, Panel A), 13 mM HPβCD (Panel B), 27 mM HPβCD (Panels C & D), and MβCD (Panel E).
Histological assessment was not performed on ears receiving salicylate treatment. OHCs appeared normal in
control ears and those receiving 13 mM HPβCD. Ears receiving 27 mM HPβCD had a variety to appearances,
from normal to severe damage. All ears treated with MβCD had severe damage.
https://doi.org/10.1371/journal.pone.0175236.g006
Intracochlear administration of 2-Hydroxypropyl-Beta-Cyclodextrin
PLOS ONE | https://doi.org/10.1371/journal.pone.0175236 April 6, 2017 9 / 20
Intracochlear administration of 2-Hydroxypropyl-Beta-Cyclodextrin
PLOS ONE | https://doi.org/10.1371/journal.pone.0175236 April 6, 2017 10 / 20
distortion product as a function of operating point is proportional to the second derivative,
and an odd order distortion product is proportional to the third derivative, of a function used
to describe the sigmoidal, saturating, nonlinear fTR (e.g., [30, 33–36].
Cochlear response harmonics to 90 dB SPL 500 Hz tone bursts were measured from ani-
mals in the control, salicylate, and 13 mM HPβCD groups (Fig 8). These are the experimental
groups where cochlear response was still present after solution administration. Artificial peri-
lymph injections (control) did not affect even order harmonic distortion (fTR asymmetry, Fig
8A, gray), but caused a small and transient decrease in odd order harmonic amplitude (fTR sat-
uration) at ~18 min. after the injection start (Fig 8A, black). Salicylate caused a slight and brief
increase in even order harmonic distortion amplitude immediately after injection (Fig 8A,
olive), and a decrease in odd order harmonic amplitude that recovered to levels greater than
pre-injection levels. (i.e., and “overshoot”; Fig 8A, green). HPβCD caused opposing effects in
even and odd order harmonic distortion. The amplitude of even order harmonics maximally
decreased at ~21 min after the injection start. In contrast, the amplitude of odd order harmon-
ics increased to a maximum at ~22 min. Both even and odd order harmonics recovered to
near pre-injection levels. We suspect that recovery of even and odd order harmonics, as well as
slight recovery of DPOAE amplitudes, may have originated from minimal damage that
Fig 7. Organ of Corti histology from each of the four cochlear turns of one exemplar guinea pig ears
after apical injection of 27 mM HPβCD. Damage was greater in the cochlear base that is tuned to high
frequencies.
https://doi.org/10.1371/journal.pone.0175236.g007
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Fig 8. Panel A: Cochlear response harmonics recorded with a round window electrode to 90 dB SPL 500 Hz
tone bursts. The semi-transparent blue rectangle identifies the 15 minute duration of solution injections into
the cochlear apex. The ranking of measurements on the y-axis was determined by the effect of the solution on
the amplitude of 3f1 of the cochlear response, with the measurements associated with the smallest effect at
the top of the figure progressing to the largest effect at the bottom of the figure. N = 3 for each treatment.
Panels B-D: Even and odd order harmonic amplitude measurements expressed as a function of operating
point estimates nonlinearities involved with transferring acoustic sound into neural excitation (fTR). Even and
odd order distortions from exemplar ears in the control and salicylate groups follow trajectories of the second
and third derivative of a function that can describe fTR and are consistent with previous experiments that
injected gel into the cochlear apex to cause sustained displacement of the organ of Corti (Panels B&C).
Effects from 13 mM HPβCD are unprecedented and cannot be explained by sustained displacement of the
organ of Corti or apparent OHC loss (Fig 6C and Fig 6B), but the marked change operating point estimates
inform the interpretation of affects fTR are the likely origin of dramatic changes to DPOAE amplitude
measurements (Fig 5).
https://doi.org/10.1371/journal.pone.0175236.g008
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precedes cell death and causes temporary functional deficit. These effects and recoveries
suggest that a function which can describe the sigmoidal, saturating, nonlinearities involved
with transferring acoustic sound into neural excitation was morphing during our acute
experiments.
We will now use a Boltzmann analysis of electrical cochlear response measurements from
exemplar ears to estimate the operating point of fTR and express harmonic distortions as a
function of operating point estimates. The cochlear response is a gross measurement of the
cochlear microphonic from inner and outer hair cells, summating potentials, changes to the
lateral wall potential from slow or sustained current through hair cells, excitatory postsynaptic
potentials, onset or phase-locked compound action potentials from cochlear regions tuned to
frequencies of the sound stimulus or those located more toward the base, and the coalescence
with spontaneous excitation of single-auditory-nerve-fibers associated with cochlear regions
that are not excited by the sound stimulus. We are thus studying cochlear nonlinearity in the
general terms of influence on DPOAE amplitude, certainly not mechanoelectric transduction
at the apical pole of an OHC as is commonly done with Boltzmann analyses. The Boltzmann
analysis of the electrical cochlear response measurements provide a more unique perspective
that builds on our qualitative description immediately above. Operating point estimates were
obtained by adjusting Boltzmann parameters until the modeled output matched empirical
cochlear responses. The Boltzmann function was Vt = VEP + (− Vsat + 2 Vsat / (1 + exp(-2 SB /
Vsat (Pt + OP)))) where VEP was a DC potential representing the endocochlear potential mag-
nitude (mV), Vsat as the saturation voltage of the Boltzmann function (mV), SB represented
the slope of the Boltzmann function at its mid-point (mV/Pa), Pt represented the input pres-
sure (Pa) as a function of time, OP represented the operating point of the Boltzmann function
(Pa).
Harmonic distortions did not markedly vary in control ears when expressed as a function
of operating point estimates (Fig 8B). Even and odd harmonic distortion variations with oper-
ating point estimates during salicylate injections (Fig 8C) were consistent with results from
previous experiments that utilized gel injections into the cochlear apex to cause sustained dis-
placement of the organ of Corti and simulate the effects of endolymphatic hydrops [33]. Varia-
tions to harmonic distortions expressed as a function of operating point estimates during 13
mM HPβCD injections were novel in that the trends deviated dramatically from the second
and third derivative of the in vivo fTR (Fig 8D). HPβCD caused unprecedented effects to physi-
ologic measurements independent of apparent OHC loss (Fig 6B) that are not consistent with
sustained displacement of the organ of Corti, such as what can happen if, for example, alter-
ation to OHC bodies manipulate stereocilia coupling to the tectorial membrane [37].
Above we used empirical measurements in a Boltzmann analysis to understand how 13
mM HPβCD treatment changed operating point estimates of in vivo fTR. We now use the
Boltzmann analysis to understand how these operating point estimates can describe the trends
in 2f1 and 3f1 harmonic distortion measurements we found during the apical injection proce-
dure (Fig 9). Recall that even (e.g., 2f1) and odd (e.g., 3f1) order harmonics respectively quan-
tify the asymmetry and saturation of in vivo fTR. Using a Boltzmann analysis, we used a
sinewave input (Pt) and systematically varied OP with estimates obtained from fitting empiri-
cal data (i.e., the x-axis values of Fig 8D). The amplitude of the harmonics in the simulated out-
put (Vt) were measured and expressed as a function of OP (Fig 9). Results show that varying
the operating point of the Boltzmann analysis yielded simulated harmonic distortions that
were qualitatively similar to empirical harmonics (cf. Figs 8 and 7A, shades of purple). These
results add additional support for the interpretation that 13 mM HPβCD caused morphing in
the sigmoidal, saturating, nonlinearities involved with transferring acoustic sound into neural
excitation during our acute experiments, without causing apparent OHC loss (Fig 6B).
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HPβCD effects on electrical cochlear responses help to understand
effects on DPOAEs
Here we discuss how the effects to the asymmetry, saturation, and sensitivity of fTR related to
the changes found to DPOAE amplitude measurements. Administering 13 mM HPβCD did
not cause apparent changes to CM amplitude recorded inside the endolymphatic space but
caused a large reduction of DPOAE amplitudes (cf. Figs 4 and 5 purple, ~15 minutes after the
start of injection). These results suggest intact mechanoelectric transduction but marked atten-
uation of cochlear amplifier gain. We investigated this further by analyzing CM measurements
made before, and 30 minutes after, the start of injection (Fig 10). Before treatment, the CM
(Fig 10A, red) fit well to a typical Boltzmann function (Fig 10A, blue) but not to a Boltzmann
function without saturation (Vsat from the Boltzmann analysis, Fig 10A, green). These fits to
pre-treatment empirical CM can be seen both in the Boltzmann analysis (Fig 10A.1) and the
time domain (Fig 10A.2 and 10A.3). During treatment, the CM (red) fit well to a simple sine
wave (Fig 10B, light green). But, to achieve a fit to a Boltzmann function, Vsat had to be set to
infinity (Fig 10B, light blue). These fits to empirical CM measurements made during treatment
can be appreciated in both the Boltzmann analysis (Fig 10B.1) and the time domain (Fig 10B.2
and 10B.3). We suspect that saturation of CM amplitude would have occurred at sound pressure
levels much higher than what was used for these experiments because there was no apparent loss
of OHC stereocilia and bodies after 13 mM HPβCD treatment. The unexpected result of normal
CM amplitude measured inside scala media in the face of maximal decreases in DPOAE ampli-
tude during treatment of 13 mM HPβCD treatment likely originate from lack of saturation to
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Fig 9. Simulated 2f1 and 3f1 harmonic distortion amplitude measurements from a Boltzmann analysis
that used a sinewave input while OP was varied. OP estimates were obtained from a previous simulation
(i.e., the x-axis values of Fig 8D). The trends of simulated 2f1 and 3f1 harmonics amplitudes expressed as a
function of OP estimates are qualitatively similar to empirical harmonic distortion amplitude measurements
made during apical injection of 13 mM HPβCD (Fig 8A, shades of purple). This simulation suggests that in
vivo OP variations accounted for essence of changes to empirical harmonics measurements from 13 mM
HPβCD treatment. Together with the results from the previous Boltzmann analysis (Fig 8B–8D), these results
show that changes to the asymmetry, saturation, and sensitivity of in vivo ftr−and origin of distortion–can
explain effects of 13 mM HPβCD on DPOAE amplitudes (Fig 5, purple).
https://doi.org/10.1371/journal.pone.0175236.g009
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and transient enhancement of EP measurements (Fig 3) made during 13 mM HPβCD treatment
could be explained if decreased current flow through OHCs increases the overall resistance





















































POST-TREATMENT 13 mM HPβCD








post-treatment Sine Wave Fit





Fig 10. An analysis of cochlear microphonic (CM, red) measured from inside the endolymphatic
space of the third cochlear turn in an exemplar ear before and after 13 mM HPβCD treatment. Pre-
treatment (top panels): the best fit to the empirical CM was achieved with a typical Boltzmann analysis (Panel
A, blue). Post-treatment (bottom panels): the best fit to empirical CM data was to a simple sine wave (Panel B,
light green). These analyses suggest that mechanoelectric transduction was effectively linearized for the
relatively high 90 dB SPLs used to evoke the CM. It is likely that saturation, or nonlinearity, of mechanoelectric
transduction after 13 mM HPβCD treatment occurs at higher sound pressure levels that what we used here.
https://doi.org/10.1371/journal.pone.0175236.g010
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OHC-generated potential, but with less shunting to perilymph the amplitude recorded from
endolymph may not be reduced to the same degree.
HPβCD does not affect the auditory nerve or lateral wall of scala media
Here we revisit the finding that ~40 min after the start of 13 mM HPβCD treatment DPOAEs
returned to near-baseline amplitudes but CAP thresholds shifted to an asymptotic level that is
consistent with fully attenuating cochlear amplifier gain (cf. Figs 1B and 4 purple). These find-
ings naturally lead to the question: Does HPβCD cause an auditory neuropathy?
Previous work found that intra-cochlear administration of the sodium channel blocker
tetrodotoxin (TTX) can be used to study excitatory post-synaptic potentials (EPSPs) recorded
with a round window electrode [38, 10]. EPSPs leading to normal spike generation have
shorter latencies than CAP latencies. But, post-treatment latencies could decrease from broad-
ened tuning caused by HPβCD affecting the cochlear amplifier, or from the need to increase
stimulus level and thus probe a wider region of cochlear tuning curves to achieve a measure-
able response in damaged ears [39–40]. Broader filters have shorter delays than sharper filters
[41]. TTX effectively causes an auditory neuropathy with raised neural thresholds in the face
of normal DPOAE amplitudes and endocochlear potential [10]. It is thus possible that the volt-
ages recorded during the asymptotic threshold shifts in Fig 1B were EPSPs masquerading as
CAPs with an amplitude the typical 10 μV criteria for thresholds while DPOAEs amplitudes
approximated pre-injection levels (cf. Figs 5 and 1B ~40 min after injection start). To address
this possibility we compared round-window electrode measurements made before and after
treatment with 13 mM HPβCD and 250 ng/ml TTX (Fig 11). We used measurements made
within the first and last 10 minutes of a 70-minute experiment that used the same 15-minute
injection procedure used in the other experiments discussed in this report. CAP measurements
before HPβCD and TTX administration are comparable, as expected (Fig 11, red). After
HPβCD treatment, the amplitude of the response was reduced but waveform morphology was
more like the pre-HPβCD waveform than the post-TTX waveform, consistent with what
would be expected by simple reduction of stimulus sound pressure level, or attenuation of
cochlear amplifier gain, that drive neural responses (Fig 11A, blue). In contrast, after TTX
administration the waveform resembles the well-known morphology of gross EPSPs as seen
from a round-window ball electrode (Fig 11A, blue). We conclude that HPβCD does not have
its primary effect by directly acting on auditory neurons.
CM amplitudes and endocochlear potential measurements made after the apical injection
stopped were minimally affected by 13 mM HPβCD. The effects of HPβCD (and salicylate) on
distortion products are thus different than those from furosemide which reduces both the
DPOAE amplitudes and the EP [42]. Our results do not suggest that HPβCD acts on the lateral
wall of scala media.
Other theories on the origin of HPβCD ototoxicity
β-cyclodextrins can have widespread actions on cochlear function, potentially impacting
any process involving cell stiffness or membrane biophysics. In other model systems, cyclo-
dextrins can impact tight junctions [43], mechanotransduction [44] and synaptic function
[45]. Without implicating any one of these, or potentially other interactions, it is clear that
the effects of β-cyclodextrins can have multiple origins. While our data suggest the origins
extend beyond outer hair cells, it remains unclear whether targets are permanently affected
by β-cyclodextrins.
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Do HPβCD effects differ between species and along the length of the
cochlear spiral?
Histological data from 27 mM HPβCD treatment showed that severe OHC and IHC damage
was more pervasive in the basal cochlear half than the apical half (Fig 7), a finding that is con-
sistent with that found by Crumling et al. [5] and Cronin et al. [6] who studied the chronic
effects of HPβCD in mice by administering systemically and directly into cerebrospinal fluid.
We suspect Cronin et al.’s drug entered the cochleae in cerebral spinal fluid through the
cochlear aqueduct in the base of scala tympani, and was therefore at a lower concentration in
the apical half of the cochlear length (cf. studies of chronic effects on measurements from mid-
frequencies with administration to the cochlear base [13,21]). In contrast, it is unlikely that
our solutions were diluted by mixing with cerebral spinal fluid because our 500 nL / min injec-
tion rate is larger than the ~30 nL / min sustained entry of cerebral spinal fluid through the
cochlear aqueduct [46]. Methodological differences aside, our histological data showing severe









Fig 11. Cochlear response measurements from two different animals made before (red) and after (blue)
treatment with HPβCD (Panel A) and TTX (Panel B) to 80 dB SPL 4 kHz tone bursts. Cochlear response
waveform maintained CAP-like morphology after HPβCD treatment, consistent with reduced mechanical
drive to neural excitation (Panel B, blue). In contrast, response waveform is EPSP-like following TTX
treatment. Unlike TTX, results from HPβCD do not support the hypothesis that the auditory nerve is a site of
action for 13 mM HPβCD.
https://doi.org/10.1371/journal.pone.0175236.g011
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Crumling et al. [5] and Cronin et al.’s [6] findings and suggests that the graded effects of
HPβCD on histological measurements along the cochlear length do not differ between species.
Histological data alone cannot determine if HPβCD has varying effects on measurements of
hearing along the cochlear length. CAP thresholds to the highest tone burst frequency (16
kHz) were affected less than to the lowest tone burst frequency (2 kHz) by 13 mM HPβCD
(Fig 1B) and salicylate (Fig 1C), but were similarly affected by 27 mM HPβCD (Fig 1D). Our
neural threshold measurements are not consistent with those from Crumling et al. [5] and
Cronin et al. [6] who found that auditory brainstem response thresholds to low-frequency
tone burst (4 kHz) were shifted by ~40 dB after HPβCD treatment but those to high-frequency
tone burst (16 & 32 kHz) shifted ~50–60 dB. The difference between our results and those
from Crumling et al. [5] and Cronin et al. [6] might be explained by their low-frequency base-
line (control) thresholds that are slightly high in the strain used [47], a result attributed to
greater OHC death. Or, disagreeing data may originate from differences in our methods used
to study the acute effects of HPβCD and their methods used to study the chronic effects of
HPβCD. Since our sets of histological data agree in that HPβCD has a lesser effect in the
cochlear apex, one would ideally want to study the chronic HPβCD effects with an approach
that could ensure treatment of the entire cochlear length in many different species and use
physiologic measurements that can be obtained throughout the cochlear length. But, as it cur-
rently stands, the presently available physiological data suggests that the graded effects of
HPβCD on measurements of hearing from along the cochlear length do differ between species.
Coupling together the available, the histological and physiological findings leads to the
hypothesis that apical cells may be less susceptible to death, but are equally susceptible to func-
tional deficit. This hypothesis predicts a continuum of a dose-response gradation from func-
tional deficit to cell death. Addressing the possibility of longitudinal gradients in cell
physiology may be a promising area of study, particularly once the perilymph concentrations
of clinically applied HPβCD are known.
Conclusions
We studied the acute effects of HPβCD injected directly into the perilymph of intact and sealed
cochleae. We found that a low-dose of HPβCD raised CAP to an extent that was consistent
with attenuating cochlear amplifier gain, had no apparent effect on the EP, altered general
nonlinearities involved with transferring acoustic sound into neural excitation without causing
apparent OHC loss, and the CM measured from inside the endolymphatic space. In contrast,
DPOAEs measured in the ear canal were greatly diminished. A high-dose of HPβCD elevated
CAP thresholds, markedly affected the EP, CM and DPOAEs, caused sporadic OHC losses
that were consistent with previous studies on the chronic effects of HPβCD. Neither the low-
or high-dose of HPβCD caused apparent disruption of the scala media lateral wall or the audi-
tory nerve. But, for the duration of our acute studies, known intra-cochlear concentrations
high-dose of HPβCD caused variable effects on OHCs throughout the length of the cochlear
spiral.
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